Non-Contrast Breast MRI Diagnosis and Risk Stratification Using DWI-Generated Synthetic Contrast Enhancement

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorPeking University People's Hospital

About this trial

This study is conducted under the ethics-approved project titled "Artificial Intelligence Solution for Simplifying the Diagnostic Workflow of Breast MRI''.The goal of this observational study is to develop an integrated breast MRI system that uses diffusion-weighted imaging (DWI) to create synthetic contrast-enhanced images. This system aims to diagnose and screen for breast cancer without the need for contrast agents, while using a generated risk score to perform imaging-based triage and risk stratification.

Participants will include people aged 18 and older who require a breast MRI either for evaluation of a suspicious finding or for high-risk screening.

This study seeks to answer two main questions:

* Can synthetic contrast-enhanced images generated from DWI match real contrast-enhanced images in their ability to distinguish benign from malignant breast lesions? * Can the risk score derived from DWI-based synthetic images enable imaging-level risk stratification, allowing people at lower risk to avoid contrast agent injection? Researchers will compare the quality of synthetic images against real contrast-enhanced images and will recruit radiologists to assess how well these images perform for diagnostic and screening tasks. MRI data from participants undergoing breast MRI will be used to train, validate, and test this integrated system.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Complete breast MRI data;

Negative pathology biopsy results or negative follow-up examinations for at least 12 months for non-cancer cases;

Positive biopsy results that meet the requirements for the pathological subtype of cancer for cancer cases;

Original data that can be used to verify clinical status, including radiological and pathological reports;

Disqualifiers

Partial mastectomy or puncture biopsy on the diseased side of the breast prior to breast MRI examination;

Poor image quality;

Implants in the affected breast;

Trial population

Participants who underwent breast MR examinations at five institutions from 2014 to 2024 were enrolled. A test cohort prospectively collected at Peking University People's Hospital Health Examination Center, was enrolled to assess the robustness of the model.

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

  • Non-contrast breast MRI diagnostic model

    Diagnostic test

    An integrated AI model capable of generating synthetic contrast-enhanced images and distinguishing between benign and malignant lesions, as well as performing risk stratification

Treatment groups

12,000 Participants
are divided into 8 treatment groups

8

Treatment groups

See each treatment group below.

Group A: Training cohort1 intervention
Group B: External test cohort A1 intervention
Group C: External test cohort B1 intervention
Group D: External test cohort C1 intervention
Group E: External test cohort D1 intervention
Group F: External test cohort E1 intervention
Group G: External test cohort F0 interventions
Group H: External test cohort G1 intervention

Trial outcomes

Primary outcomes

1

MRI examination

A multi-parameter contrast-enhanced breast MRI examination was performed, including fat-suppressed T2-weighted imaging, diffusion-weighted imaging, dynamic contrast-enhanced sequences, and fat-suppressed T1-weighted imaging.

Time frame
Baseline

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: